Harmony Biosciences Holdings Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

Harmony Biosciences Holdings hat in der Vergangenheit keine Dividende gezahlt.

Wichtige Informationen

n/a

Dividendenausschüttung

n/a

Ausschüttungsquote

Durchschnittlicher Branchenertrag	2.2%
Nächster Dividendenzahlungstermin	n/a
Ex-Dividendendatum	n/a
Dividende pro Aktie	n/a
Gewinn pro Aktie	US$2.42
Erwartete Dividendenrendite in 3 Jahren	0%

Aktuelle Dividendenentwicklung

Keine Aktualisierungen

Recent updates

Investors Holding Back On Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Jun 07

Harmony Biosciences Holdings, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

May 03

These 4 Measures Indicate That Harmony Biosciences Holdings (NASDAQ:HRMY) Is Using Debt Safely

Apr 04

Market Cool On Harmony Biosciences Holdings, Inc.'s (NASDAQ:HRMY) Earnings

Feb 09

Fewer Investors Than Expected Jumping On Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Mar 21

Does Harmony Biosciences Holdings (NASDAQ:HRMY) Deserve A Spot On Your Watchlist?

Dec 01

Harmony Biosciences: In Harmony

Sep 23

We Ran A Stock Scan For Earnings Growth And Harmony Biosciences Holdings (NASDAQ:HRMY) Passed With Ease

Aug 05

Harmony Biosciences Non-GAAP EPS of $0.57 misses by $0.06, revenue of $107M beats by $6.25M

Aug 02

Harmony Biosciences Holdings' (NASDAQ:HRMY) Promising Earnings May Rest On Soft Foundations

Aug 17

Stabilität und Wachstum des Zahlungsverkehrs

Rufe Dividendendaten ab

Stabile Dividende: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Dividende je Aktie von HRMY in der Vergangenheit stabil war.

Wachsende Dividende: Unzureichende Daten, um festzustellen, ob die Dividendenzahlungen von HRMY gestiegen sind.

Dividendenrendite im Vergleich zum Markt

Harmony Biosciences Holdings Dividendenrendite im Vergleich zum Markt

Wie sieht die Dividendenrendite von HRMY im Vergleich zum Markt aus?
Segment	Dividendenrendite
Unternehmen (HRMY)	n/a
Untere 25 % des Marktes (US)	1.5%
Markt Top 25 % (US)	4.7%
Branchendurchschnitt (Pharmaceuticals)	2.2%
Analystenprognose in 3 Jahren (HRMY)	0%

Bemerkenswerte Dividende: Es ist nicht möglich, die Dividendenrendite von HRMY im Vergleich zu den unteren 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Hohe Dividende: Es ist nicht möglich, die Dividendenrendite von HRMY im Vergleich zu den besten 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Gewinnausschüttung an die Aktionäre

Abdeckung der Erträge: Unzureichende Daten zur Berechnung der Ausschüttungsquote von HRMY, um festzustellen, ob die Dividendenzahlungen durch die Gewinne gedeckt sind.

Barausschüttung an die Aktionäre

Cashflow-Deckung: Es ist nicht möglich, die Nachhaltigkeit der Dividende zu berechnen, da HRMY keine Ausschüttungen gemeldet hat.

Harmony Biosciences Holdings Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

Wichtige Informationen

Aktuelle Dividendenentwicklung

Recent updates

Harmony Biosciences Receives U.S. Food and Drug Administration Approval for WAKIX (Pitolisant) in Pediatric Patients with Narcolepsy

Harmony Biosciences Holdings, Inc. Reaffirms Sales Guidance for the Year 2024

Investors Holding Back On Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

HARMONY Biosciences Presents Positive Data for Pitolisant in the Treatment of Excessive Daytime Sleepiness and FATIGUE in Myotonic Dystrophy Type 1

Consensus EPS estimates fall by 21%

Harmony Biosciences Holdings, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Harmony Biosciences Holdings, Inc. Provides Revenue Guidance for the Year 2024

First quarter 2024 earnings: EPS exceeds analyst expectations

Harmony Biosciences Holdings, Inc. to Report Q1, 2024 Results on Apr 30, 2024

Harmony Biosciences Holdings, Inc., Annual General Meeting, May 29, 2024

These 4 Measures Indicate That Harmony Biosciences Holdings (NASDAQ:HRMY) Is Using Debt Safely

Executive VP exercised options and sold US$269k worth of stock

Harmony Biosciences Initiates Global Phase 3 Registrational Trial (Tempo Study) of Pitolisant in Patients with Prader-Willi Syndrome

Executive VP & Chief Commercial Officer notifies of intention to sell stock

Consensus EPS estimates fall by 11%

Full year 2023 earnings: EPS misses analyst expectations

U.S. Food and Drug Administration Grants Priority Review to Harmony Biosciences' Application for WAKIX® (pitolisant) in Pediatric Narcolepsy

Harmony Biosciences Holdings, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Market Cool On Harmony Biosciences Holdings, Inc.'s (NASDAQ:HRMY) Earnings

Harmony Biosciences Holdings, Inc. Provides Preliminary Revenue Guidance for the Fourth Quarter and Full Year 2023 and for the Year 2024

Harmony Biosciences Holdings, Inc. Announces Positive Topline Data from Phase 2 Signal Detection Study Evaluating Pitolisant in Adult Patients with Myotonic Dystrophy Type 1

Harmony Biosciences Holdings, Inc. Appoints Peter Anastasiou as Class III Director and Member of the Compensation Committee of the Board

Harmony Biosciences Holdings, Inc. Appoints Peter Anastasiou to its Board of Directors

Investor sentiment improves as stock rises 26%

Harmony Biosciences Holdings, Inc. (NasdaqGM:HRMY) announces an Equity Buyback for $200 million worth of its shares.

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Harmony Biosciences Showcases the Newest Patients At the Heart and Progress At the Heart Award Recipients

Harmony Biosciences Holdings, Inc. to Report Q3, 2023 Results on Oct 31, 2023

Harmony Biosciences Holdings, Inc. Announces Topline Data from Phase 3 Intune Study Evaluating Pitolisant in Patients with Idiopathic Hypersomnia

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 35%

Harmony Biosciences Holdings, Inc. (NasdaqGM:HRMY) completed the acquisition of Zynerba Pharmaceuticals, Inc. (NasdaqCM:ZYNE).

Harmony Biosciences Holdings, Inc. (NasdaqGM:HRMY) announces an Equity Buyback for $125 million worth of its shares.

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Harmony Biosciences Holdings, Inc. Announces Plans to Initiate Phase 3 Registration Study of Pitolisant in Prader-Willi Syndrome

Harmony Biosciences Holdings, Inc. Completes Enrollment of Phase 3 Registrational Intune Study in Idiopathic Hypersomnia

Harmony Biosciences Holdings, Inc. to Present New Wanix (Pitolisant) Safety and Efficacy Data

Harmony Biosciences Holdings, Inc. Appoints Kumar Budur as Chief Medical Officer

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 8.4% to US$59.89

Executive VP & CFO exercised options and sold US$514k worth of stock

Investor sentiment deteriorates as stock falls 27%

Fewer Investors Than Expected Jumping On Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Full year 2022 earnings: EPS exceeds analyst expectations

Harmony Biosciences Holdings, Inc. to Report Q4, 2022 Results on Feb 21, 2023

Harmony Biosciences Holdings, Inc. Announces CEO Changes

Executive VP & Chief Strategy Officer exercised options and sold US$2.0m worth of stock

Does Harmony Biosciences Holdings (NASDAQ:HRMY) Deserve A Spot On Your Watchlist?

Consensus EPS estimates increase by 119%

Executive VP & Chief Medical Officer exercised options and sold US$703k worth of stock

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Harmony Biosciences Holdings, Inc. Announces Topline Results from Phase 2 Proof-Of-Concept Study Evaluating Pitolisant for Excessive Daytime Sleepiness in Patients with Prader-Willi Syndrome

Harmony Biosciences Holdings, Inc. to Report Q3, 2022 Results on Nov 01, 2022

Executive VP & Chief Commercial Officer exercised options and sold US$444k worth of stock

Harmony Biosciences: In Harmony

President exercised options and sold US$1.7m worth of stock

Consensus forecasts updated

We Ran A Stock Scan For Earnings Growth And Harmony Biosciences Holdings (NASDAQ:HRMY) Passed With Ease

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Harmony Biosciences Non-GAAP EPS of $0.57 misses by $0.06, revenue of $107M beats by $6.25M

Harmony Biosciences Holdings, Inc. to Report Q2, 2022 Results on Aug 02, 2022

Investor sentiment improved over the past week

President exercised options and sold US$899k worth of stock

Harmony Biosciences: Steady Revenue Generator Looking For A Future

Investor sentiment improved over the past week

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Harmony Biosciences Initiates Phase 3 Trial of Pitolisant in Adult Patients with Idiopathic Hypersomnia

Harmony Biosciences Holdings, Inc. to Report Q1, 2022 Results on May 03, 2022

Harmony Biosciences Holdings, Inc., Annual General Meeting, May 20, 2022

Chief Commercial Officer exercised options and sold US$371k worth of stock

President exercised options and sold US$854k worth of stock

Consensus EPS estimates fall by 14%

Harmony Biosciences: Strong Growth At A Reasonable Price

Chief Commercial Officer exercised options and sold US$316k worth of stock

Full year 2021 earnings: EPS misses analyst expectations